High in vitro efficacy of Nyda L, a pediculicide containing dimeticone.
Abstract
BACKGROUND
The therapy of pediculosis remains a common problem in clinical practice. As resistance to commonly used chemical pediculicides is constantly increasing, there is a need for new effective compounds.STUDY DESIGN
The efficacy of Nyda L, a new pediculicide containing a high concentration of dimeticone, was assessed in an in vitro trial and compared with three reference products (Hedrin containing 4% dimeticone, Lyclear containing 1% permethrin, and Prioderm containing 1% malathion) and a negative control group. Head lice were collected from heavily infested patients in a resource-poor community in Northeast Brazil, where no resistance against pediculicides has been reported thus far. In each of the five groups, 50 adult fully vital lice were tested. We used a dip test (immersing head lice in the undiluted products for 3 min, washing off products after 20 min). Using predefined criteria for mortality, the lice were monitored at different points in time, for a period of 24 h.RESULTS
Nyda L and Prioderm killed all head lice already after 5 min. The efficacy of Nyda L was better than of Lyclear. Lice treated with Hedrin resurrected after several hours and did not show a significantly higher mortality compared with the control group after 24 h.CONCLUSION
Nyda L can be regarded as a very efficacious pediculicidal compound, killing all lice in vitro within 5 min.Links
Authors+Show Affiliations
,Department of Community Health, School of Medicine, Federal University of Ceará, Fortaleza, Brazil.
,Source
Journal of the European Academy of Dermatology and Venereology : JEADV 21:10 2007 Nov pg 1325-9
MeSH
AnimalsDimethylpolysiloxanes
Hair Preparations
In Vitro Techniques
Insecticide Resistance
Insecticides
Lice Infestations
Malathion
Pediculus
Permethrin
Scalp Dermatoses
Pub Type(s)
Comparative StudyJournal Article
Research Support, Non-U.S. Gov't
Language
eng
PubMed ID
17958836
Citation
* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - High in vitro efficacy of Nyda L, a pediculicide containing dimeticone.
AU - Oliveira,F A S,
AU - Speare,R,
AU - Heukelbach,J,
PY - 2007/10/26/pubmed
PY - 2008/3/18/medline
PY - 2007/10/26/entrez
SP - 1325
EP - 9
JF - Journal of the European Academy of Dermatology and Venereology : JEADV
JO - J Eur Acad Dermatol Venereol
VL - 21
IS - 10
N2 - BACKGROUND: The therapy of pediculosis remains a common problem in clinical practice. As resistance to commonly used chemical pediculicides is constantly increasing, there is a need for new effective compounds. STUDY DESIGN: The efficacy of Nyda L, a new pediculicide containing a high concentration of dimeticone, was assessed in an in vitro trial and compared with three reference products (Hedrin containing 4% dimeticone, Lyclear containing 1% permethrin, and Prioderm containing 1% malathion) and a negative control group. Head lice were collected from heavily infested patients in a resource-poor community in Northeast Brazil, where no resistance against pediculicides has been reported thus far. In each of the five groups, 50 adult fully vital lice were tested. We used a dip test (immersing head lice in the undiluted products for 3 min, washing off products after 20 min). Using predefined criteria for mortality, the lice were monitored at different points in time, for a period of 24 h. RESULTS: Nyda L and Prioderm killed all head lice already after 5 min. The efficacy of Nyda L was better than of Lyclear. Lice treated with Hedrin resurrected after several hours and did not show a significantly higher mortality compared with the control group after 24 h. CONCLUSION: Nyda L can be regarded as a very efficacious pediculicidal compound, killing all lice in vitro within 5 min.
SN - 0926-9959
UR - https://www.unboundmedicine.com/medline/citation/17958836/High_in_vitro_efficacy_of_Nyda_L_a_pediculicide_containing_dimeticone_
L2 - https://doi.org/10.1111/j.1468-3083.2007.02258.x
DB - PRIME
DP - Unbound Medicine
ER -